Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Randomized Phase I/II Trial of SCM-AGH in Moderate to Severe Atopic Dermatitis
KCT0004806Phase 2Not yet recruiting
- Sponsor
- SCM Lifescience Co., Ltd.
- Start
- Mar 2020
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SCM-AGH in atopic dermatitis (AD), sponsored by SCM Lifescience Co., Ltd.. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
SCM-AGH
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on KCT0004806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004806.